China Genetic Testing Market Overview,2030

The genetic testing market in China is witnessing remarkable expansion, fueled by rapid technological advancements, strong government support for precision medicine, and a growing middle class that prioritizes preventive healthcare. Over the past decade, China has emerged as one of the world’s most dynamic hubs for genetic research and diagnostics. The government’s “Healthy China 2030” initiative and National Precision Medicine Plan have been major driving forces, integrating genomics into healthcare, disease prevention, and drug development. Local companies and research institutes have invested heavily in sequencing technologies, automation, and data analysis tools, making genetic testing more accessible and affordable to the public. The growing prevalence of hereditary diseases, cancers, and rare genetic disorders has increased the demand for early diagnostic and predictive testing across hospitals and clinics. Major players like BGI Genomics, Novogene, and Berry Genomics have revolutionized the industry with large-scale sequencing facilities and partnerships with hospitals nationwide. Additionally, the Chinese population’s genetic diversity and vast biobank projects such as the China National GeneBank are creating massive datasets that enhance the understanding of disease mechanisms and genetic variations. Public awareness of the benefits of genetic testing, particularly for prenatal screening, oncology, and carrier testing, is expanding rapidly, supported by campaigns emphasizing family health and long-term wellness.

According to the research report, ""China Genetic Testing Market Overview, 2030,"" published by Bonafide Research, the China Genetic Testing market is anticipated to add to more than 3.02 Billion by 2025–30. China’s genetic testing market continue to multiply as the country moves toward personalized and data-driven medicine. One of the most promising areas is pharmacogenomics, which is enabling healthcare providers to tailor treatments based on individual genetic profiles, reducing side effects and improving drug efficacy. The rise of direct-to-consumer (DTC) genetic testing services has further accelerated market growth, with millions of consumers interested in ancestry tracing, nutrition, and fitness genomics. The integration of artificial intelligence (AI) and big data analytics into genetic research is also transforming diagnostics and predictive health modeling, allowing for faster and more accurate results. China’s vast technological ecosystem, driven by leading companies such as Huawei and Alibaba Health, is fostering collaboration between the tech and healthcare sectors, giving rise to intelligent healthcare solutions. Moreover, supportive regulations from the National Health Commission and evolving ethical guidelines ensure safe data handling and privacy protection, although balancing innovation with ethical oversight remains an ongoing challenge. The country’s strong investment in talent development and international collaborations with biotech firms in the U.S. and Europe further enhance its competitiveness. Unique to China is the scale of its public health genomics projects, aimed at mapping population-wide genetic risks and using that data to improve national healthcare policies. With its combination of government-backed infrastructure, entrepreneurial innovation, and digital transformation, China is positioning itself as a global leader in genetic testing where genomics, technology, and healthcare intersect to shape the future of personalized medicine.

The product segment includes testing kits, reagents, sequencing platforms, consumables, and bioinformatics software used for diagnostics and research purposes. The strong demand for these products stems from the country’s large population base, increasing healthcare awareness, and the rising prevalence of genetic and chronic diseases such as cancer, cardiovascular disorders, and congenital abnormalities. China has developed a robust manufacturing ecosystem for molecular diagnostic products, driven by domestic companies like BGI Genomics, Berry Genomics, AmoyDx, and Daan Gene, which produce affordable and high-quality testing kits and sequencing systems. The government’s support through initiatives such as the “Healthy China 2030” plan and “China Precision Medicine Initiative” has further boosted product innovation and commercialization. On the other hand, the service segment is expanding even more rapidly, driven by growing demand for clinical testing, genetic counseling, and personalized healthcare services. Hospitals, diagnostic laboratories, and fertility centers across major cities such as Beijing, Shanghai, and Shenzhen are increasingly incorporating genetic testing into routine care. The proliferation of direct-to-consumer (DTC) testing services for ancestry, wellness, and disease risk assessment is also reshaping consumer engagement in the market. Companies like 23Mofang and WeGene are making genetic testing more accessible to the public, while clinical testing remains primarily physician-directed and regulated by the National Health Commission.

The adoption of NGS is driven by its ability to analyze large-scale genomic data with high accuracy, making it invaluable in oncology, rare disease detection, and population health studies. The Chinese government has heavily invested in developing domestic sequencing capabilities, leading to the rise of globally competitive firms like BGI Genomics and Novogene, which offer advanced sequencing platforms and services at competitive prices. Polymerase Chain Reaction (PCR) remains widely used for single-gene testing, infectious disease detection, and genetic screening in hospitals and diagnostic centers due to its cost-effectiveness and quick turnaround time. Microarrays continue to play a significant role in pharmacogenomics, gene expression studies, and prenatal diagnostics, while In-situ Hybridization (ISH) including fluorescence-based FISH techniques is commonly used in cancer pathology for detecting chromosomal abnormalities and genetic rearrangements. Emerging techniques such as CRISPR-based diagnostics, digital PCR, and AI-powered bioinformatics tools are also gaining traction, supported by China’s rapidly advancing biotech sector. The government’s focus on building national genomic databases and biobanks, such as the China National GeneBank, further enhances the capacity for large-scale genetic research and data analysis. In addition, favorable regulatory reforms and investments in artificial intelligence are improving the efficiency of genomic data interpretation and clinical application. As domestic innovation accelerates, China is not only reducing its dependence on imported sequencing systems but is also positioning itself as a global leader in genetic testing technologies.

Oncology testing has seen explosive growth due to the rising incidence of cancer and the government’s strong push toward precision oncology. Leading hospitals such as the Peking Union Medical College Hospital and Fudan University Cancer Center are increasingly utilizing tumor genetic profiling, companion diagnostics, and liquid biopsy-based assays to guide targeted therapies. Companies like AmoyDx and Burning Rock Biotech specialize in NGS-based cancer diagnostics, making personalized oncology a mainstream practice. Reproductive health testing is another dominant area, encompassing non-invasive prenatal testing (NIPT), carrier screening, and preimplantation genetic testing (PGT). With a growing awareness of maternal and child health, these tests have become routine in both urban and semi-urban healthcare facilities. Domestic providers such as Berry Genomics and BGI have made NIPT widely available at affordable prices, leading to one of the highest adoption rates globally. Genetic disease testing is expanding rapidly, supported by national programs aimed at early diagnosis and management of hereditary disorders like thalassemia, cystic fibrosis, and metabolic syndromes. Large-scale newborn screening initiatives and regional genetic centers are helping detect rare diseases early, reducing long-term healthcare costs. Beyond these, other clinical applications such as pharmacogenomics, nutrigenomics, and preventive health testing are gaining importance. Pharmacogenomic testing is increasingly being integrated into hospital practices to optimize drug prescriptions and minimize adverse drug reactions, aligning with the country’s precision medicine goals. Additionally, China’s advancements in digital health integration, AI analytics, and population genome sequencing are enhancing the utility of genetic data in clinical decision-making.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Genetic Testing Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Type
• Products (Consumables, Equipment)
• Services

By Technique
• Next-generation Sequencing (NGS)
• Polymerase Chain Reaction
• Microarrays
• In-situ Hybridization
• Others

By Application
• Oncology Testing
• Reproductive Health Testing
• Genetic Diseases (Rare & Common)
• Other Clinical (Pharmacogenomics, etc.) 
Show more